Short-Term Efficacy and Safety Profile of Generic Bortezomib in the Treatment of Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2021.01.022
- Author:
Rong-Qiong LIAO
1
;
Xiao-Jing LIN
1
;
Xiang-Long LI
1
;
Xun NI
1
;
Wen-Feng LUO
1
;
Pan ZHAO
1
;
Jing CHEN
1
;
Jin WEI
1
;
Xing-Li ZOU
2
Author Information
1. Department of Hematology, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
2. Department of Hematology, The Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China,E-mail: zxldylan@nsmc.edu.cn.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Bortezomib/therapeutic use*;
Dexamethasone/therapeutic use*;
Disease-Free Survival;
Humans;
Middle Aged;
Multiple Myeloma/drug therapy*;
Neoplasm Recurrence, Local;
Retrospective Studies;
Transplantation, Autologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2021;29(1):137-144
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the short-term efficacy and safety of generic bortezomib in the treatment of Chinese patients with multiple myeloma (MM).
METHODS:Clinical data of 62 MM patients (median age of 62 years) who had accepted at least 2 cycles of chemotherapy based on generic bortezomib in our center from December 2017 to July 2019 were retrospectively analyzed, including 47 newly diagnosed patients and 15 with disease recurrence or progression.
RESULTS:Anemia, renal dysfunction, hypoproteinemia and high level of β
CONCLUSION:The disease severity can be rapidly alleviated after generic bortezomib-based chemotherapy, and a favorable short-term efficacy and survival have been observed with a generally acceptable toxicity profile. However, the long-term outcomes will be examined through further follow-up.
